Abstract:Abstract Background SPR206 is a novel intravenously (IV)-administered next-generation polymyxin being developed for the treatment of multi-drug resistant (MDR) Gram-negative (GN) infections. A Phase 1 bronchoalveolar lavage (BAL) study was conducted to evaluate SPR206 safety and PK in plasma and pulmonary matrices (ELF and AM) in healthy volunteers. Methods Subjects received 100 mg SPR206 administered intravenously over 1 h q8h for 3 consecutive doses. Blood samples were collected pre-dose (second and third dose) and at 2, 3, 4, 6, and 8 h after the start of the last dose. Each subject underwent one standardized bronchoscopy with BAL at 2, 3, 4, 6 or 8 hours after the start of the third IV infusion. Concentrations of SPR206 in plasma, BAL, and cell pellet were measured with a validated LC-MS/MS assay. Plasma, ELF, and AM PK parameters were determined by noncompartmental analysis. SPR206 AUC0–8 in ELF and AM were calculated using the mean concentration values at the BAL sampling times. SPR206 AUC0–8 ratios of ELF and AM to unbound plasma were determined using plasma protein binding value of 8.6%. Results Thirty-four subjects were enrolled and completed the study and 30 of 34 completed bronchoscopy. The mean SPR206 Cmax concentrations in plasma, ELF, and AM were 4395.0, 735.5, and 860.6 ng/mL, respectively. Mean AUC0-8 h values in plasma, ELF, and AM concentrations were 20120.7, 4859.8, and 6026.4 ng*h/mL, respectively--leading to a free ELF to plasma concentration ratio of 0.264 and free AM to plasma ratio of 0.328. Importantly, mean concentrations of SPR206 in the ELF achieved lung exposures above its minimum inhibitory concentration for the targeted gram-negative pathogens for the entire 8-hour dosing interval. Figure 1 displays the mean (±SD) SPR206 total and unbound plasma, ELF, and AM concentrations at the BAL sampling times. Overall, SPR206 was well tolerated; 22 subjects (64.7%) experienced at least 1 TEAE, mostly mild with a few moderate. The most frequently reported TEAEs were oral paresthesia [10 subjects (29.4%)] and nausea [2 subjects (5.9%)], which were reversible. Conclusion This study demonstrates pulmonary penetration of SPR206 and supports further development of SPR206 for the treatment of patients with pneumonia caused by MDR GN infections. Figure 1.Mean (±SD) plasma (total and unbound), epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations of SPR206 in healthy adult subjects. This study was conducted in collaboration with, and with financial support from, the United States Department of Defense (Award No. W81XWH1910295). Disclosures Keith A. Rodvold, PharmD, Spero Therapeutics: Advisor/Consultant|Spero Therapeutics: Honoraria Justin Bader, n/a, Spero Therapeutics: Employee Vipul K. Gupta, Ph.D., Spero Therapeutics: Employee Troy Lister, Ph.D., Spero Therapeutics: Employee Praveen Srivastava, Ph.D., Spero Therapeutics: Employee Jon Bruss, M.D., Spero Therapeutics: Employee.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial

A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension

Safety, Tolerability, and Pharmacokinetics of the Novel Pan-Phosphodiesterase Inhibitor ZSP1601 in Healthy Subjects: a Double-Blinded, Placebo-Controlled First-in-human Single-Dose and Multiple-Dose Escalation and Food Effect Study

First-in-human study to assess the safety, tolerability, and pharmacokinetics of intravenous SHPL-49 following single- and multiple-ascending-dose administration in healthy adults

First-in-human Phase 1 Study of SPH4336, a Novel Cyclin-Dependent Kinase 4/6 Inhibitor, in Patients with Advanced Solid Tumors.

The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in chinese healthy subjects: a randomized, placebo-controlled, double-blind, single-dose and dose-escalation phase I trial

Safety, Tolerability, and Pharmacokinetic of HY0721 in Chinese Healthy Subjects: a First-in-human Randomized, Double-Blind, Placebo-Controlled Dose Escalation Phase I Study

The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in Chinese healthy subjects

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study

Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

A Phase Ib Study of SHR-1210 Plus Apatinib for Heavily Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Patients.

Open-label, Dose-Escalation Phase 1a Study of SPH5030, a Tyrosine Kinase Inhibitor (TKI) Targeting HER2, in Patients with HER2 Positive Advanced Solid Tumors.

625. SPR206 Pharmacokinetics (PK) in Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) in Healthy Adult Subjects

S-16-4: PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY RESULTS FROM A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF THE SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR CIN-107

PRECLINICAL AND CLINICAL EFFICACY AND SAFETY OF A NOVEL MULTI-TARGET SMALL MOLECULE MT-1207 FOR HYPERTENSION

Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone antagonist in healthy premenopausal women

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study

Phase 1, Single‐Center, Double‐Blind, Randomized, Placebo‐Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP‐624 in Healthy Adults

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with advanced solid tumors.